Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Summary

This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.

Timeline

Start

2014-06

Primary completion

2016-01

Completion

2016-06

Outcome

Outcome not reported

Stopped: “Study terminated due to lack of efficacy”

Drugs

Indications